Oral combination therapy to treat staphylococcal infections using dicloxacillin and P911
Official title: Pre-clinical Safety and Toxicology Studies of a PO-administered b-lactam-tarocin combination agent to treat methicillin susceptible and resistant staphylococci
Funded at Hackensack University Medical Center · NIH-11372908 · Data updated 2026-11-12
A new oral drug combination aiming to safely kill staph infections, including resistant strains, by pairing dicloxacillin with a beta-lactam potentiator for outpatient use.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | June 20, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $606,933 |
| NIH project number | 5U19AI189168-02 |
| Project ID | NIH-11372908 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with suspected or confirmed staphylococcal infections who may require outpatient or step-down therapy once a safe, orally bioavailable option is established.
✕Less likely to help
Patients without staphylococcal infections or those requiring inpatient IV therapy not addressed by this preclinical program may not benefit.
What this research studies
This grant supports preclinical studies to develop a first-in-class, bactericidal oral therapy for staphylococcal infections, regardless of methicillin resistance. Researchers will perform non-GLP scale‑up, in vitro genotoxicity tests, and single‑dose monkey pharmacokinetic studies to build a complete pharmacology and toxicology package. The work is designed to support IND-enabling development and identify backup compounds if needed, with a focus on safety and metabolic profiles. If successful, the project could lead to a future outpatient treatment option with potentially fewer adverse effects than current oxazolidinones.
Why it matters
Potential benefit: If successful, patients could have an effective oral treatment for staphylococcal infections, including resistant strains, suitable for step-down or outpatient care.
How similar studies have gone: Preclinical development of antibiotic combinations and PCCs has advanced in other programs, but this is a novel first‑in‑class oral bactericidal approach with a unique beta-lactam potentiator.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Roemer, Terry — Hackensack University Medical Center
- Study coordinator: Roemer, Terry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.